Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study.
Henderson A, Paterson DL, Chatfield MD, Tambyah PA, Lye DC, De PP, Lin RTP, Chew KL, Yin M, Lee TH, Yilmaz M, Cakmak R, Alenazi TH, Arabi YM, Falcone M, Bassetti M, Righi E, Rogers BA, Kanj SS, Bhally H, Iredell J, Mendelson M, Boyles TH, Looke DFM, Runnegar NJ, Miyakis S, Walls G, Khamis MAI, Zikri A, Crowe A, Ingram PR, Daneman N, Griffin P, Athan E, Roberts L, Beatson SA, Peleg AY, Cottrell K, Bauer MJ, Tan E, Chaw K, Nimmo GR, Harris-Brown T, Harris PNA; MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN).
Henderson A, et al. Among authors: de pp.
Clin Infect Dis. 2021 Dec 6;73(11):e3842-e3850. doi: 10.1093/cid/ciaa1479.
Clin Infect Dis. 2021.
PMID: 33106863
Clinical Trial.